GlassScriptPhysician profile
Elliot D Rosenstein
NPI 1174585145
$100,694.80
in general payments reported to CMS, 2019-2025
33 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $25K · 2021: $8,917 · 2022: $2,619 · 2023: $11K · 2024: $1,639 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Food and Beverage: $5,229 · Travel and Lodging: $1,957 · Education: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,172.50 |
| Food and Beverage | $5,229.44 |
| Travel and Lodging | $1,956.50 |
| Education | $396.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $61,743.18 | 2019-2025 | Orencia, Sotyktu |
| Abbvie INC. | $16,493.25 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $9,156.29 | 2019-2025 | |
| Ucb, INC. | $6,938.83 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $2,064.96 | 2019-2023 | Krystexxa |
| Amgen INC. | $962.91 | 2019-2025 | Evenity, Tavneos, Enbrel |
| Janssen Biotech, INC. | $937.14 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Glaxosmithkline, LLC. | $538.40 | 2019-2024 | Benlysta |
| Pfizer INC. | $298.50 | 2019-2025 | |
| Genzyme Corporation | $186.31 | 2019-2025 | |
| Lilly USA, LLC | $147.32 | 2019-2024 | Taltz |
| Argenx US, INC. | $137.26 | 2025 | Vyvgart Hytrulo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.56 | 2019-2025 | Ofev, Jascayd, Cyltezo |
| Radius Health, INC. | $118.10 | 2019-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $97.15 | 2019-2024 | Strensiq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $85.63 | 2023-2025 | Hadlima, Renflexis |
| Pacira Therapeutics, INC. | $76.62 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $71.80 | 2022-2024 | Saphnelo |
| Sobi, INC | $64.53 | 2019-2025 | |
| Bioventus LLC | $56.73 | 2019-2025 | Durolane |
| Medexus Pharma, INC. | $51.95 | 2019-2020 | |
| Genentech USA, INC. | $48.60 | 2019-2020 | |
| Celgene Corporation | $44.46 | 2019 | |
| Hikma Pharmaceuticals USA | $39.00 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $31.37 | 2024 | Arcalyst |
| Mallinckrodt Hospital Products INC. | $30.44 | 2024-2025 | Acthar |
| Fresenius Kabi USA, LLC | $30.04 | 2023-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $27.47 | 2022-2023 | Arcalyst |
| Aurinia Pharma U.S., INC. | $18.68 | 2022 | |
| Ani Pharmaceuticals, INC. | $18.36 | 2025 | Sovuna |
| Ferring Pharmaceuticals INC. | $17.83 | 2023 | Euflexxa |
| Sanofi-Aventis U.S. LLC | $15.82 | 2020 | |
| Sebela Pharmaceuticals INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Rosenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.